{"id":"W2559804019","doi":"10.1016/s0140-6736(16)32455-2","title":"Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial","year":2016,"lang":"en","type":"article","venue":"The Lancet","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":2211,"is_retracted":false,"has_abstract":false,"ca_institutions":"BC Cancer Agency; Princess Margaret Cancer Centre","funders":"National Cancer Institute; EMD Serono; Ipsen; Astellas Pharma; F. Hoffmann-La Roche; Eisai; Sanofi; Amgen; Pfizer; Genentech; Celgene; AstraZeneca; Eli Lilly and Company","keywords":"Atezolizumab; Medicine; Metastatic Urothelial Carcinoma; Clinical endpoint; Oncology; Internal medicine; Cisplatin; Chemotherapy; Progression-free survival; Phases of clinical research; Response Evaluation Criteria in Solid Tumors; Cancer; Bladder cancer; Urology; Clinical trial; Urothelial carcinoma; Immunotherapy; Pembrolizumab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null}